Sight SciencesSGHT +0.33%72 FCF Margin % is -35.99% as of Mar. 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sight Sciences ranks worse than 74.85% on this metric.
The historical rank and industry rank for Sight Sciences's FCF Margin % or its related term are showing as below:
SGHT'
s FCF Margin % Range Over the Past 10 Years
Min: -199.8 Med: -108.42 Max: -28.47
Current: -31.65
During the past 8 years, the highest FCF Margin % of Sight Sciences was -28.47%. The lowest was -199.80%. And the median was -108.42%.
SGHT's FCF Margin % is ranked worse than 74.85% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs SGHT: -31.65
Sight Sciences FCF Margin % Related Terms
Sight Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sight Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sight Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a FCF Margin % of -35.99% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #610 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is Sight Sciences' FCF Margin % too high?
Sight Sciences' current FCF Margin % is -35.99%. Based on the distribution chart, Sight Sciences ranks #610 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' FCF Margin % compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #610 out of 815 companies for FCF Margin %. This places Sight Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sight Sciences and its competitors. Sight Sciences's current FCF Margin % is -35.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.52 — trading 22.9% above its estimated fair value. The current FCF Margin % is -35.99%. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sight Sciences (SGHT), the current FCF Margin % is -35.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.52 is trading 22.9% above its estimated GF Value™ of $4.49.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
FCF Margin %: -35.99%
GF Value™: $4.49 vs. price of $5.52 (22.9% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
